Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience

Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. M...

Full description

Bibliographic Details
Main Authors:	Aynur Acibuca, Ahmet Sezer, Mustafa Yilmaz, Ahmet Taner Sumbul, Senol Demircan, Ibrahim Haldun Muderrisoglu, Ozgur Ozyilkan
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-12-01
Series:	Journal of International Medical Research
Online Access:	https://doi.org/10.1177/03000605211053755

Similar Items

Pertuzumab-mediated Cardiotoxicity: A Single Center Study.
by: Özgür Özyilkan, et al.
Published: (2023-06-01)

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
by: Kimberly S. Corbin, et al.
Published: (2020-09-01)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
by: Matthew N. Mills, et al.
Published: (2021-03-01)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
by: Tatiana Strava Corrêa, et al.
Published: (2018-05-01)

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
by: Chung Young Kim, et al.
Published: (2019-08-01)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
by: Peipei Liu, et al.
Published: (2020-06-01)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
by: Miwa Fujihara, et al.
Published: (2021-11-01)

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats
by: Eun-Jeong Jeon, et al.
Published: (2023-02-01)

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).
by: Yuan-Chiang Chung, et al.
Published: (2015-01-01)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
by: Matteo Allegretti, et al.
Published: (2021-11-01)

<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
by: Gaia Griguolo, et al.
Published: (2020-07-01)

Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
by: Adam Sharp, et al.
Published: (2015-02-01)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra DR, et al.
Published: (2014-07-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
by: Tal Sella, et al.
Published: (2022-11-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
by: Fabien Moinard-Butot, et al.
Published: (2022-06-01)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
by: Neelima Denduluri, et al.
Published: (2022-12-01)

Enhanced Toxicity With Trastuzumab Emtansine And Concurrent Adjuvant Radiotherapy: Non-Consecutive Case Series
by: Jade Soo, et al.
Published: (2023-04-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
by: Heidi Egloff, et al.
Published: (2018-08-01)

Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure
by: A. Falcón González, et al.
Published: (2021-01-01)

RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
by: Olav Engebraaten, et al.
Published: (2021-11-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
by: Parvin F. Peddi, et al.
Published: (2014-09-01)

Ado-trastuzumab emtansine (T-DM1) for a case of HER2-amplified metastatic extramammary Paget's disease of scrotum: Clinical next-generation sequencing for precision medicine
by: Chih-Yu Chen, et al.
Published: (2020-01-01)

Nöroendokrin tümörlerin klinikohistopatolojik özellikleri ve tedavi sonuçları: tek merkez deneyimi
by: Ali Murat SEDEF, et al.
Published: (2018-09-01)

Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2–overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study
by: Viraj Lavingia, et al.
Published: (2022-11-01)

Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study
by: Eyyup Cavdar, et al.
Published: (2022-08-01)

Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis
by: Amani M. Cobert, et al.
Published: (2020-04-01)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016-01-01)

Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
by: Samy Hakroush, et al.
Published: (2021-11-01)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)

Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
by: Saeed S. Akhand, et al.
Published: (2021-01-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report
by: Ihab Hassanieh, et al.
Published: (2018-07-01)

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
by: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, et al.
Published: (2019-09-01)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
by: Marcos Aurélio Fonseca Magalhães Filho, et al.
Published: (2022-05-01)